Lymphoid-like fibroblast reticular cells in the secondary lymphoid tissues and tumor microenvironment induce immunosuppression via maintaining the tolerogenic function of myeloid populations

The object of this article was to identify important methodological problems related to studying vulnerable groups. Ethnic minorities are difficult to contact and likely to refuse participation in social-science research, including victimization studies. This is problematic since difficulties accessing a group for research purposes may result in a lack of research; in turn leading to a knowledge gap concerning some groups lived experiences. Based on interviews with members of the Roma community we identity difficulties related to gaining access to the population for research purposes. Results show that researchers studying minorities need to gain cultural understanding and competence

Glucuronidase beta is an early predictive marker for the use of antidepressant in the treatment of glioma patients

Purpose: To screen early targets and investigate the potential molecular mechanisms involved in the use of antidepressant in the treatment of glioma. Methods: The GSE89873 dataset, including expression levels of C6 cells under antidepressant treatment, non-antidepressant drug treatment, and untreated cells (control), was downloaded from database. Differentially expressed genes (DEGs) between antidepressant treatment and untreated cells, and between non-antidepressant drug treatment and untreated cells were identified and annotated. Genes that were significantly related to different drug treatment conditions were screened. Results: In all, 416 differentially expressed genes (DEGs) were selected between cells of the antidepressant treatment and control groups, while 650 DEGs were selected between cells of the non-antidepressant treatment and control groups. The 402 overlapping DEGs were significantly associated with the apoptotic process, transforming growth factor beta receptor signaling pathway, and cell cycle arrest (p < 0.05). The DEGs ACOX1, ACSL1, GSTM3, and GSTP1 were significantly related to hormonal therapy (p < 0.05). Glucuronidase beta (GUSB) was significantly associated with age and targeted molecular therapy (p < 0.05). The GUSB was also significantly associated with overall survival time (p < 0.05). It is one of the unique DEGs in the antidepressant treatment group that participates in the drug metabolism-cytochrome P450 metabolic pathway. Conclusion: Glucuronidase beta may be a specific biomarker for the early response of antidepressants to glioma treatment. This should, however, be further investigated to validate this finding